IP Library › Granted Patent US 7,645,761
Granted Patent B2
US 7,645,761 · App. 11/821,384 · Granted Jan 12, 2010

Indoline derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,645,761
App. No.
11/821,384
Granted
Jan 12, 2010
Kind
B2
Abstract

This invention relates to substituted indoline derivative compounds which are antagonists of the progesterone receptor, their preparation and pharmaceutical utility, particularly including contraception and treatment of benign or malignant neoplastic diseases, having the general structure: wherein R 1 and R 2 may be single substituents or fused to form spirocyclic rings.

Claims (86)

1. A method of inducing contraception in a mammal, the method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of the structure:

wherein:

R 1 and R 2 form a double bond to C(CH 3 ) 2 , C(cycloalkyl), O, or C(cycoether);

R 3 is selected from the group consisting of H, OH, NH 2 , C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, C 3 to C 6 alkenyl, alkynyl, substituted alkynyl, and COR A ;

R A is selected from the group consisting of H, C 1 to C 3 alkyl, substituted C 1 to C 3 alkyl, C 1 to C 3 alkoxy, substituted C 1 to C 3 alkoxy, C 1 to C 3 aminoalkyl, and substituted C 1 to C 3 aminoalkyl;

R 4 is selected from the group consisting of H, halogen, CN, NH 2 , C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, C 1 to C 6 alkoxy, substituted C 1 to C 6 alkoxy, C 1 to C 6 aminoalkyl, and substituted C 1 to C 6 aminoalkyl;

R 5 is a five membered ring of the structure:

wherein:

U is O, S, or NR 6 ,

R 6 is H, C 1 to C 3 alkyl, or C 1 to C 4 CO 2 alkyl,

X′ is selected from the group consisting of halogen, CN, NO 2 , C 1 to C 3 alkyl and C 1 to C 3 alkoxy; with the proviso that when X′ is CN, U is not NR 6 ;

Y′ is selected from the group consisting of H, F, CN, NO 2 , and C 1 to C 4 alkyl;

or a pharmaceutically acceptable salt thereof.

2. A method of inducing contraception in a mammal, the method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of the structure:

wherein:

R 1 and R 2 form a double bond to C(CH 3 ) 2 , C(cycloalkyl), O, or C(cycloether);

R 3 is selected from the group consisting of H, OH, NH 2 , C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, C 3 to C 6 alkenyl, alkynyl, substituted alkynyl, and COR A ;

R A is selected from the group consisting of H, C 1 to C 3 alkyl, substituted C 1 to C 3 alkyl, C 1 to C 3 alkoxy, substituted C 1 to C 3 alkoxy, C 1 to C 3 aminoalkyl, and substituted C 1 to C 3 aminoalkyl;

R 4 is selected from the group consisting of H, halogen, CN, NH 2 C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, C 1 to C 6 alkoxy, substituted C 1 to C 6 alkoxy, C 1 to C 6 aminoalkyl, and substituted C 1 to C 6 aminoalkyl;

R 5 is a six membered ring of the structure:

wherein:

X 1 is CX 2 ;

X 2 is halogen, CN or NO 2 ;

or a pharmaceutically acceptable salt thereof.

3. A method of inducing contraception in a mammal, the method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of the structure:

wherein:

R 1 and R 2 form a double bond to C(CH 3 ) 2 , C(cycloalkyl), O, or C(cycloether);

R 3 is selected from the group consisting of H, OH, NH 2 , C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, C 3 to C 6 alkenyl, alkynyl, substituted alkynyl, and COR A ;

R A is selected from the group consisting of H, C 1 to C 3 alkyl, substituted C 1 to C 3 alkyl, C 1 to C 3 alkoxy, substituted C 1 to C 3 alkoxy, C 1 to C 3 aminoalkyl, and substituted C 1 to C 3 aminoalkyl;

R 4 is selected from the group consisting of H, halogen, CN, NH 2 , C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, C 1 to C 6 alkoxy, substituted C 1 to C 6 alkoxy, C 1 to C 6 aminoalkyl, and substituted C 1 to C 6 aminoalkyl;

R 5 is selected from the group consisting of a) and b):

a) a five or six membered heterocyclic ring having in its backbone 1, 2, or 3 heteroatoms selected from the group consisting of O, S, SO, SO 2 and NR 6 and containing one or two independent substituents selected from the group consisting of H, halogen, CN, NO 2 , C 1 to C 3 alkyl, C 1 to C 3 alkoxy, C 1 to C 3 aminoalkyl, COR D , and NR E COR D ;

R D is H, C 1 to C 3 alkyl, substituted C 1 to C 3 alkyl, aryl, substituted aryl, C 1 to C 3 alkoxy, substituted C 1 to C 3 alkoxy, C 1 to C 3 aminoalkyl, or substituted C 1 to C 3 aminoalkyl;

R E is H, C 1 to C 3 alkyl, or substituted C 1 to C 3 alkyl;

R 6 is H or C 1 to C 3 alkyl; and

b) an indol-4-yl, indol-7-yl or benzo-2-thiophene moiety, the moiety being optionally substituted by from 1 to 3 substituents selected from the group consisting of halogen, lower alkyl, CN, NO 2 , lower alkoxy, and CF 3 ;

or a pharmaceutically acceptable salt thereof.

4. A method of hormone replacement therapy, the method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound the structure:

wherein:

R 1 and R 2 form a double bond to C(CH 3 ) 2 , C(cycloalkyl), O, or C(cycloether);

R 3 is selected from the group consisting of H, OH, NH 2 , C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, C 3 to C 6 alkenyl, alkynyl, substituted alkynyl, and COR A ;

R A is selected from the group consisting of H, C 1 to C 3 alkyl, substituted C 1 to C 3 alkyl, C 1 to C 3 alkoxy, substituted C 1 to C 3 alkoxy, C 1 to C 3 aminoalkyl, and substituted C 1 to C 3 aminoalkyl;

R 4 is selected from the group consisting of H, halogen, CN, NH 2 , C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, C 1 to C 6 alkoxy, substituted C 1 to C 6 alkoxy, C 1 to C 6 aminoalkyl, and substituted C 1 to C 6 aminoalkyl;

R 5 is selected from the group consisting of a) and b):

a) a five or six membered heterocyclic ring having in its backbone 1, 2, or 3 heteroatoms selected from the group consisting of O, S, SO, SO 2 and NR 6 and containing one or two independent substituents selected from the group consisting of H, halogen, CN, NO 2 , C 1 to C 3 alkyl, C 1 to C 3 alkoxy, C 1 to C 3 aminoalkyl, COR D , and NR E COR D ;

R D is H, C 1 to C 3 alkyl, substituted C 1 to C 3 alkyl, aryl, substituted aryl, C 1 to C 3 alkoxy, substituted C 1 to C 3 alkoxy, C 1 to C 3 aminoalkyl, or substituted C 1 to C 3 aminoalkyl;

R E is H, C 1 to C 3 alkyl, or substituted C 1 to C 3 alkyl;

R 6 is H or C 1 to C 3 alkyl; and

b) an indol-4-yl, indol-7-yl or benzo-2-thiophene moiety, the moiety being optionally substituted by from 1 to 3 substituents selected from the group consisting of halogen, lower alkyl, CN, NO 2 , lower alkoxy, and CF 3 ;

or a pharmaceutically acceptable salt thereof.

5. A method of inducing contraception or hormone replacement therapy in a mammal, the method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of the formula:

wherein:

R 1 and R 2 are selected from the group consisting of H, alkyl, substituted alkyl, OH, O(alkyl), O(substituted alkyl), OAc, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkylaryl, alkylheteroaryl, 1-propynyl, and 3-propynyl;

R 3 is selected from the group consisting of H, OH, NH 2 , C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, C 3 to C 6 alkenyl, alkynyl, substituted alkynyl, and COR A ;

R A is selected from the group consisting of H, C 1 to C 3 alkyl, substituted C 1 to C 3 alkyl, C 1 to C 3 alkoxy, substituted C 1 to C 3 alkoxy, C 1 to C 3 aminoalkyl, and substituted C 1 to C 3 aminoalkyl;

R 4 is selected from the group consisting of H, halogen, CN, NH 2 , C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, C 1 to C 6 alkoxy, substituted C 1 to C 6 alkoxy, C 1 to C 6 aminoalkyl, and substituted C 1 to C 6 aminoalkyl;

R 5 is selected from the group consisting of a), b), and c):

a) a five membered heterocyclic ring having in its backbone 1, 2, or 3 heteroatoms selected from the group consisting of O, S, SO, SO 2 and NR 6 and containing one or two independent substituents selected from the group consisting of H, halogen, CN, NO 2 , C 1 to C 3 alkyl, C 1 to C 3 alkoxy, C 1 to C 3 aminoalkyl, COR D , and NR E COR D ;

with the proviso that when the five-membered heterocyclic ring having in its backbone one NR 6 heteroatom is attached at the 2-position on said ring, the CN substituent is attached at the 1-,3-, 4-, or 5-position of said ring;

b) a six membered hetcrocyclic ring having in its backbone 1 or 2 heteroatoms selected from the group consisting of O, S, SO, SO 2 and NR 6 and containing one or two independent substituents selected from the group consisting of H, halogen, CN, NO 2 , C 1 to C 3 alkyl, C 1 to C 3 alkoxy, C 1 to C 3 aminoalkyl, COR D , and NR E COR D ;

R D is H, C 1 to C 3 alkyl, substituted C 1 to C 3 alkyl, aryl, substituted aryl, C 1 to C 3 alkoxy, substituted C 1 to C 3 alkoxy, C 1 to C 3 aminoalkyl, or substituted C 1 to C 3 aminoalkyl;

R E is H, C 1 to C 3 alkyl, or substituted C 1 to C 3 alkyl;

R 6 is H or C 1 to C 3 alkyl; and

c) an indol-4-yl, indol-7-yl or benzo-2-thiophene moiety, the moiety being optionally substituted by from 1 to 3 substituents selected from the group consisting of halogen, lower alkyl, CN, NO 2 , lower alkoxy, and CF 3 ;

or a pharmaceutically acceptable salt thereof.

6. A method of inducing contraception or hormone replacement therapy in a mammal, the method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound selected from the group consisting of 5-(3,3-Dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-4-methyl thiophene-2-carbonitrile; 4-(3,3-Dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-furan-2-carbonitrile; 5-(3,3-Dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-furan-2-carbonitrile; 2-(3 ,3-Dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-2-nitro-pyrrole; 5-(3,3-Dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-thiophene-2-carbonitrile; and 3,3-Dimethyl-5-(5-nitro-thiophene-2-yl)-1,3-dihydro-indol-2-one; or a pharmaceutically acceptable salt thereof.

7. A method of inducing contraception in a mammal, the method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of the formula:

wherein:

R 1 and R 2 are selected from the group consisting of H, alkyl, substituted alkyl, OH, O(alkyl), O(substituted alkyl), OAc, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkylaryl, alkylheteroaryl, 1-propynyl, and 3-propynyl;

R 3 is selected from the group consisting of H, OH, NH 2 , C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, C 3 to C 6 alkenyl, alkynyl, substituted alkynyl, and COR A ;

R A is selected from the group consisting of H, C 1 to C 3 alkyl, substituted C 1 to C 3 alkyl, C 1 to C 3 alkoxy, substituted C 1 to C 3 alkoxy, C 1 to C 3 aminoalkyl, and substituted C 1 to C 3 aminoalkyl;

R 4 is selected from the group consisting of H, halogen, CN, NH 2 , C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, C 1 to C 6 alkoxy substituted C 1 to C 6 alkoxy, C 1 to C 6 aminoalkyl, and substituted C 1 to C 6 aminoalkyl;

R 5 is a six membered ring with the structure shown below:

wherein:

X 1 is N;

or pharmaceutically acceptable salt thereof.

8. A method of hormone replacement therapy, the method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of the formula:

wherein:

R 1 and R 2 are selected from the group consisting of H, alkyl, substituted alkyl, OH, O(alkyl), O(substituted alkyl), OAc, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkylaryl, alkylheteroaryl, 1-propynyl, and 3-propynyl;

R 3 is selected from the group consisting of H, OH, NH 2 , C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, C 3 to C 6 alkenyl, alkynyl, substituted alkynyl, and COR A ;

R A is selected from the group consisting of H, C 1 to C 3 alkyl, substituted C 1 to C 3 alkyl, C 1 to C 3 alkoxy, substituted C 1 to C 3 alkoxy, C 1 to C 3 aminoalkyl, and substituted C 1 to C 3 aminoalkyl;

R 4 is selected from the group consisting of H, halogen, CN, NH 2 , C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, C 1 to C 6 alkoxy, substituted C 1 to C 6 alkoxy, C 1 to C 6 aminoalkyl, and substituted C 1 to C 6 aminoalkyl;

R 5 is a six membered ring with the structure shown below:

wherein:

X 1 is N;

or pharmaceutically acceptable salt thereof.